Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1. To assess the response rate of ONTAK in Systemic Mastocytosis (SM) patients.
Secondary Objectives:
1. To assess the safety of ONTAK in SM patients.
2. To evaluate the time to progression and duration of response following treatment with
ONTAK.